Icon (NASDAQ:ICLR)‘s stock had its “overweight” rating reiterated by equities researchers at KeyCorp in a report released on Monday, November 13th, The Fly reports. They currently have a $125.00 price objective on the medical research company’s stock, up from their previous price objective of $115.00. KeyCorp’s price target would suggest a potential upside of 7.25% from the company’s current price. KeyCorp also issued estimates for Icon’s Q4 2017 earnings at $1.41 EPS, Q1 2018 earnings at $1.42 EPS, Q2 2018 earnings at $1.47 EPS, Q3 2018 earnings at $1.52 EPS, Q4 2018 earnings at $1.56 EPS, FY2018 earnings at $5.97 EPS and FY2019 earnings at $5.89 EPS. The analysts noted that the move was a valuation call.
Several other research analysts have also weighed in on ICLR. Mizuho lifted their price objective on Icon from $104.00 to $108.00 and gave the stock a “neutral” rating in a research report on Thursday, July 27th. Credit Suisse Group restated a “buy” rating on shares of Icon in a research note on Friday, July 28th. Jefferies Group reiterated a “buy” rating on shares of Icon in a research note on Sunday, July 30th. SunTrust Banks upgraded Icon from a “hold” rating to a “buy” rating and lifted their price target for the company from $93.00 to $126.00 in a research note on Monday, July 31st. Finally, Zacks Investment Research downgraded Icon from a “buy” rating to a “hold” rating in a research note on Friday, August 18th. Four investment analysts have rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $121.00.
Shares of Icon (NASDAQ:ICLR) traded down $0.26 during trading hours on Monday, reaching $116.55. The company had a trading volume of 211,256 shares, compared to its average volume of 253,436. The company has a market cap of $6,325.50, a price-to-earnings ratio of 22.42, a P/E/G ratio of 1.80 and a beta of 0.57. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.90 and a current ratio of 1.90. Icon has a twelve month low of $73.76 and a twelve month high of $124.48.
Several institutional investors have recently bought and sold shares of ICLR. Koch Industries Inc. lifted its position in shares of Icon by 17,508.8% during the 2nd quarter. Koch Industries Inc. now owns 666,140 shares of the medical research company’s stock worth $659,000 after buying an additional 662,357 shares in the last quarter. FMR LLC lifted its position in shares of Icon by 38.4% during the 2nd quarter. FMR LLC now owns 2,291,005 shares of the medical research company’s stock worth $224,037,000 after buying an additional 635,950 shares in the last quarter. Janus Henderson Group PLC lifted its position in shares of Icon by 48.4% during the 2nd quarter. Janus Henderson Group PLC now owns 1,068,159 shares of the medical research company’s stock worth $104,488,000 after buying an additional 348,292 shares in the last quarter. Mckinley Capital Management LLC Delaware lifted its position in shares of Icon by 2,674.8% during the 2nd quarter. Mckinley Capital Management LLC Delaware now owns 338,520 shares of the medical research company’s stock worth $33,104,000 after buying an additional 326,320 shares in the last quarter. Finally, Principal Financial Group Inc. lifted its position in shares of Icon by 71.5% during the 3rd quarter. Principal Financial Group Inc. now owns 768,471 shares of the medical research company’s stock worth $87,513,000 after buying an additional 320,356 shares in the last quarter. 89.95% of the stock is currently owned by hedge funds and other institutional investors.
Icon Company Profile
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
Receive News & Ratings for Icon Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon Plc and related companies with our FREE daily email newsletter.